| 02.09.24 | Roche to shrink R&D team; Takeda snags ph. 2 narcolepsy win but misses extra indication

Laden...

9 maanden geleden

Html
Tekst


A message from Tanvex

Today’s Big News

Feb 9, 2024

Roche to shrink product development team, mainly impacting contractors

Takeda powers toward pivotal trials after phase 2b narcolepsy win but pauses multi-indication dream

Metagenomi, Telomir head to Nasdaq this morning in double test case for preclinical IPOs

Synlogic reaches end of line, laying off 90% of staff and ceasing operations after phase 3 fail

Chutes & Ladders—Ex-CRISPR Tx CMO lands at Takeda

Could Dupixent find a new life targeting ‘memory’ B cells to treat allergies?


A message from Medical Affairs Strategic Summit

Featured

Roche to shrink product development team, mainly impacting contractors

By Max Bayer

Roche is laying off employees within its product development team, with the total reductions slated to impact less than 6% of full-time employees in the unit. The pharma group reported 7% growth in its non-COVID business.

Takeda powers toward pivotal trials after phase 2b narcolepsy win but pauses multi-indication dream

By Nick Paul Taylor

Takeda’s narcolepsy work has finally yielded a phase 2b win, albeit with a blemish. After axing one asset over liver toxicity, the Japanese drugmaker’s continued faith in the mechanism has been rewarded with a primary endpoint hit—but the midphase program only supports progression in one form of the disease.

Metagenomi, Telomir head to Nasdaq this morning in double test case for preclinical IPOs

By James Waldron

After a string of IPO success stories for clinical-stage biotechs so far this year, two companies look set to test whether they can expect the same warm reaction on the public markets this morning despite not yet having a candidate in human trials.

Biotech in 2024: Opportunities, Trends & Challenges

DDI Potential of Major Pharmaceutical Excipients on Transporters & Enzymes

While individually inactive, these ingredients can cause unexpected drug interactions with the drug they are administered with and co-medications… View Symposium Recording >>

Synlogic reaches end of line, laying off 90% of staff and ceasing operations after phase 3 fail

By James Waldron

Synlogic’s dreams have gone up in smoke on the news that the pivotal phase 3 study of its lead phenylketonuria drug is on track to miss its primary endpoint.

Chutes & Ladders—Ex-CRISPR Tx CMO lands at Takeda

By Max Bayer,Gabrielle Masson

Well that didn’t take long! Three days after Phuong Khanh Morrow, M.D., formally departed from CRISPR Therapeutics, the ex-chief medical officer landed at Takeda as the new head of the oncology therapeutic area.

Could Dupixent find a new life targeting ‘memory’ B cells to treat allergies?

By Helen Floersh

A new discovery might offer some answers about why allergies happen—as well as open up a potential role for approved biologic drugs like Dupixent or Xolair.

PBMs take bulk of blame as senators question BMS, J&J and Merck CEOs on high drug prices in US

By Kevin Dunleavy

CEOs from Bristol Myers Squibb, Johnson & Johnson and Merck faced tough questions from senators on why prices for drugs in the U.S. exceed those in other countries.

Invitae stock dries up amid reports of a looming bankruptcy filing

By Andrea Park

Shares of Invitae are trading for less than a nickel apiece after a report surfaced earlier this week claiming the genetic testing company is on the verge of filing for bankruptcy.

‘The Top Line’: The most anticipated drug launches of 2024

By Ayla Ellison,Ben Adams

This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.

Fierce Pharma Asia—Leqembi’s slow uptake; Takeda’s pipeline culls; Roche’s world-first nod

By Angus Liu

Eisai said uptake of its Biogen-partnered Alzheimer's drug, Leqembi, will likely miss an early launch target. Takeda cut several cancer candidates in its latest pipeline clear-out. Roche's subcutaneous C5 inhibitor won its world-first approval in China. And more.

Fierce podcasts

Don’t miss an episode

‘The Top Line’: The most anticipated drug launches of 2024

'Podnosis': Catching up with the Fierce 15 of 2019 (part 2)

'The Top Line': Navigating the future of medical AI

Infographic: Why Detecting Particles at Each Lifecycle Step Is Vital

Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.

Resources

Whitepaper

The Oncology Market – 2023 Year in Review

This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Developing and Manufacturing Drugs with HPAPIs

Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient.